Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliograf¿a
[64]
Allergy 1994;49(Suppl 19):5.
[65]
Nasal cytology, lung biology in health and disease. Vol 123. Rhinitis Mechanisms and management. New York: Marcel Dekker Inc., 1999.
[66]
Valoración de la obstrucción nasal. En: Kimmelman CP, editor. Valoración y tratamiento otorrinolaringológicos en el consultorio. Clin Otorrinolaringol North Am (ed. esp.) 1992;4:847-60.
[67]
Diagnóstico y tratamiento de la obstrucción nasal. En: López Amado M, editor. Diagnóstico y tratamiento de la patología ORL en atención primaria. Barcelona: Masson, 2000; p. 91-101.
[68]
The impact of allergic rhnitis on quality of life and other aireway diseases. Summary of an European conference. Allergy 1998; 53(Suppl 41).
[69]
Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Joint Council on Allergy, Asthma and Immunology, 1998. Ann Allergy Asthma Immunol 1998; 81:478-518.
[70]
Fiberoctic rhinoscopy. En: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic diseases. New York: Marcel Dekker, 2000; p. 233-44.
[71]
Imaging of the upper airway and sinuses. En: Kemp SF, Lockey RF, editors. Diagnostic testing of allergic diseases. New York: Marcel Dekker, 2000; p. 263-86.
[72]
Cytology. En: Myngind N, Naclerio RM, editors. Allergic and non-allergic rhinitis: clinical aspects. Philadelphia: WB Saunders Company, 1993; p. 66-81.
[73]
Problems in defining normal limits for serum IgE. J Allergy Clin Immunol 1990;440-8.
[74]
Nasal polips: medical or surgical management? Clin Exp Allergy 1996;26(Suppl 3):23-30.
[75]
Allergy 1999;54(Suppl 55).
[76]
Adouble blind study of efectiveness of a high efficiency particulate air (HEPA) filter in the treatment of patients with perennial allergic rhinitis and asthma. J Allergy Clin Inmunol 1990;85:1050-7.
[77]
Pathophysiology and therapy for allergic and non-allergic rhinitis: an updatep review. Allergy Asthma Proc 1997;8:213-20.
[78]
Use of nasal esteroids in managing allergic rhinitis. J Allergy Clin Immunol 1999;103:S388-94.
[79]
Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624-9.
[80]
A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:323-30.
[81]
The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis. Allergy Asthma Proc 1998;19:23-9.
[82]
Ideal pharmacoterapy for allergic rhinitis. J Allergy Clin Immunol 1999;103:S386-7.
[83]
A clinical overview of Tilarin. Allergy 1996(28 Suppl):28-34.
[84]
Antihistamines. En: Kaplan AP, editor. Allergy. 2nd ed. Philadelphia: WB Saunders Co., 1997.
[85]
Risks of non-sedating antihistamines. Lancet 1997;349:1322.
[86]
Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000;79:690-3.
